Dr. Jonathan Aschoff

ROTH Capital Partners

Dr. Jonathan Aschoff is a managing director at Opus National Capital Markets. Prior to joining the firm in 2016, he held positions as a senior biotechnology analyst at Brean Murray, Carret & Co. and Friedman Billings Ramsey & Co. Inc., as a senior analyst at what is now RBC Inc. and also served as an analyst at Sturza Institutional Research. Prior to his work on Wall Street, Dr. Aschoff was a research technician at New England Medical Center. It was at Tufts University that Dr. Aschoff earned his Ph.D. in molecular biology and microbiolog,y as well as his bachelor's degree in biology.

Recent Articles

Dermatology Co.'s Target Price Much Higher Than Current 09/20/2022

The biopharma's strategic marketing campaign "should continue growing U.S. sales to current and new customers," noted a ROTH Capital Partners report.

Analyst Says Biopharma's New Inhaled Antifungal Drug Shows Promise 09/12/2022

Trial results are expected later this month, but anecdotal data available now suggest the findings should be positive, noted a ROTH Capital Partners report.


Recent Quotes

"The freedom to forego Phase 3 testing for Rexista has saved IPCI at least $20M."

— Dr. Jonathan Aschoff, Brean Capital (4/15/16)
more >

"We look forward to SNGX's next clinical steps."

— Dr. Jonathan Aschoff, Brean Capital (3/25/15)
more >

"SNGX's current cash should support operations into Q4/14."

— Dr. Jonathan Aschoff, Brean Capital (3/26/14)
more >

"INO is differentiated by its use of electroporation in conjunction with DNA in its therapeutic and preventative vaccines."

— Dr. Jonathan Aschoff, Brean Capital (2/7/14)
more >

"SNGX has sufficient cash to support its operations into Q1/15."

— Dr. Jonathan Aschoff, Brean Capital (11/12/13)
more >

"With its licensing agreement with Roche, we believe INO will be able to focus on developing its remaining pipeline."

— Dr. Jonathan Aschoff, Brean Capital (9/10/13)
more >



Due to permission requirements, not all quotes are shown.